Search

Objective: To investigate the expression of structural maintenance of chromosome 4 (SMC4) in breast cancer and its prognostic value. Methods: The expression of SMC4 gene in breast cancer tissues and its correlation with the clinicopathological characteristics of patients were analyzed using the TIMER, GEPIA, UALCAN and GEO databases. The expression of SMC4 protein in breast cancer and adjacent normal tissues was detected using immunohistochemical (IHC) staining. Correlations between SMC4 expression and clinicopathological features of breast cancer were evaluated. The relationship between SMC4 expression and survival of patients with breast cancer was evaluated by Kaplan-Meier, GEPIA database, Cox proportional hazards regression model. Results: Bioinformatics analysis showed that the mRNA level of SMC4 in breast cancer tissues was significantly higher than that in normal adjacent tissues (P < 0.01), and was closely related to clinical stage, lymph node metastasis and chemotherapy resistance (all P < 0.05). IHC staining showed that the positive and strong positive rates of SMC4 in breast cancer tissues were significantly higher than those in normal adjacent tissues (all P < 0.05). The high protein expression of SMC4 was closely related to the age, clinical stage and lymph node metastasis of breast cancer patients (all P < 0.05). The cumulative survival rate of patients in SMC4 low expression group was significantly higher than that in the SMC4 high expression group, especially in patients with HER2+ breast cancer (P < 0.05). Additionally, SMC4 is an independent risk factor for prognosis in patients with breast cancer. Conclusion: SMC4 is highly expressed in breast cancer tissues. High SMC4 expression is closely related to lymph node metastasis, clinical stage, and prognosis of patients with breast cancer, making it a potential marker for the diagnosis and prognosis of breast cancer. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the effects of wild-type vesicular stomatitis virus strain (VSV-IN) on immunomodulation and tumour metastasis in mouse triple negative breast cancer (TNBC) 4T1 cell transplantation model mice. Methods: After VSV-IN infected 4T1 cells with MOI=1, MOI=10 and MOI=100 for 12, 24 and 48 h, 4T1 cell mortality was detected by CCK-8 method, migration ability by scratch healing assay, and the expressions of E-cadherin, MMP-2 and MMP-9 mRNA by qPCR. The fat pads of female BALB/c mice were inoculated with 0.1 mL of 4T1 cells with a cell density of 1x106 cells/mL to construct a 4T1 cell-loaded mouse model. When the tumour volume reached 200 mm³, the mice were injected intratumorally with PBS, taxol (TAX) (15 mg/kg), and VSV (1x106 pfu) once a week, respectively. After 4 administrations, mice were executed, stripped of intact grafted tumour tissues, and tumour volume and mass were measured. Histopathological sections of the lungs were stained with H-E, and tumour metastatic nodules of the lungs were observed. The proportion of T-cell subpopulations in the spleen was detected by flow cytometry. The levels of serum IL-6 and TNF-α were detected by ELISA. The expression levels of migration-related proteins in mammary gland tumours were analysed by using the online analysis of GEPIA. The expressions of MMP-2, MMP-9 and E-cadherin in mouse tumours were detected by immunohistochemistry, and the affinity of G and M proteins of VSV-IN and ERK2 and E-cadherin was predicted by protein-protein docking technology. Results: The mortality rate of 4T1 cells after 48 hours of VSV treatment at MOI=10 and 100 were significantly higher than that of the control group (P<0.01). Compared with that of the control group, the cell migration rate of the VSV-IN group (MOI=10) was significantly lower (P<0.01), and the relative expression of MMP-9 mRNA was significantly lower (P<0.05). Compared with those in the mice of the control group, transplanted tumours in the mice of the VSV-IN group grew more slowly, and their endpoint volume was significantly reduced (P<0.05). The number of lung metastatic nodules in the mice of the VSV group was significantly less than that of the control group ([12.86±1.86] vs [24±3.67], P<0.01). The proportions of splenic CD4+ T and CD8+ T cells in the VSV group were significantly higher (both P<0.05). The serum TNF-α and IL-6 levels were significantly higher (both P< 0.01). GEPIA tool analysis revealed that the expression levels of E-cadherin and MMP-9 were higher in breast cancer tissues than in paracancerous tissues (P<0.05). The expression of MMP-9 in the tumour cells of the mice in the VSV-IN group was significantly lower than that in the control group (P<0.05). The binding free energies of G and M proteins of VSV-IN to ERK2 were -11.7 kcal/mol and -6.4 kcal/mol, respectively. Conclusion: Wild-type VSV-IN inhibits the growth and metastasis of transplanted tumours in 4T1 tumor-bearing mice, which may be related to its promotion of anti-tumour immunity and modulation of the expression of migration-related proteins. [ABSTRACT FROM AUTHOR]

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

ObjectiveTo explore the metabolic changes during the development of Tupaia belangeri breast tumors, to investigate the close relationship between the changes of serum metabolic substances and the occurrence and progression of tumors, and to screen for biomarkers reflecting the progression of breast tumors.MethodsBreast tumors in Tupaia belangeri were induced by orally administering 7,12-dimethylbenzoanthracene (DMBA) three times, with a 15-day interval between each administration, along with a high-fat and high-sugar diet. The DMBA-induced breast cancer group and the DMBA-inducedwithout breast cancer group were compared with the control group. Untargeted determination of serum metabolites was performed using gas chromatography-time-of-flight mass spectrometry (GC-TOFMS) in DMBA-induced Tupaia belangeri with breast cancer, DMBA-induced without breast cancer and the control group. Multidimensional statistical analysis including unsupervised principal component analysis (PCA), and orthogonal partial least squares analysis (OPLS-DA) were conducted. Furthermore, t-test was used for intergroup differential comparison. Differential metabolites were screened under VIP>1 and P1, P1, P1, P

Breast cancer ranks as one of the most prevalent malignancies globally, predominantly affecting the female population. Notably, the expression of class IIa histone deacetylases (HDACs), particularly histone deacetylase 5 (HDAC5), exhibits significant variation between breast cancer patients and healthy individuals. This differential expression positions HDAC5 as a promising biomarker for breast cancer and potentially other cancer types. Furthermore, HDAC5 has emerged as a credible molecular target for anticancer therapeutics. This review aims to concisely summarize the structural characteristics of HDAC5, its contributory role in the pathogenesis of breast cancer, and the therapeutic potential of HDAC5 inhibitors. We will discuss the feasibility of detecting HDACs, designing histonedeacetylase inhibitors (HDACi), and identifying effective drug targets in conjunction with HDACi. Our goal is to offer strategic insights for advancing breast cancer treatment, focusing on the application of HDACi in managing breast cancer tumors. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

This article describes a case of breast cancer post-surgery. During the outpatient chemotherapy, oral mucositis and hair loss caused by chemotherapy drugs led to anxiety, which led to the motivation of nursing care. During the nursing period from February 1st to April 30th, 2021, data were collected through direct nursing, observation, interview, medical record review and social software interaction. The evaluation was based on physical, psychological, social, spiritual levels and combined with human figure drawing evaluation. Analysis established health problems as anxiety, oral mucositis and physical and mental image disorders. The intervention included: using Swanson's caring theory to establish a good relationship between nurses and patients; taking the initiative to care and accompany patients; encourage joint participation in care plans; teach stress relief, oral care and methods to cope with hair loss and appearance changes; introduce cases to share experiences; strengthen positive attitudes and self-confidence, and successfully complete chemotherapy. It is hoped that the human figure drawing evaluation approach will be promoted to the cross-team discussion in the hospital, so as to quickly grasp the patient's problems, enhance the nursing consensus, and promote the nursing results into the family-centered nursing model, so as to improve the quality and effectiveness of nursing. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To explore the metabolic changes during the development of Tupaia belangeri breast tumors, to investigate the close relationship between the changes of serum metabolic substances and the occurrence and progression of tumors, and to screen for biomarkers reflecting the progression of breast tumors. Methods Breast tumors in Tupaia belangeri were induced by orally administering 7, 12- dimethylbenzoanthracene (DMBA) three times, with a 15-day interval between each administration, along with a high-fat and high-sugar diet. The DMBA-induced breast cancer group and the DMBA-inducedwithout breast cancer group were compared with the control group. Untargeted determination of serum metabolites was performed using gas chromatography-time-of-flight mass spectrometry (GCTOFMS) in DMBA-induced Tupaia belangeri with breast cancer, DMBA-induced without breast cancer and the control group. Multidimensional statistical analysis including unsupervised principal component analysis (PCA), and orthogonal partial least squares analysis (OPLS-DA) were conducted. Furthermore, t-test was used for intergroup differential comparison. Differential metabolites were screened under VIP>1 and P<0.05 conditions, and significantly changing differential metabolites were identified using the HMDB online database. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database was utilized to enrich metabolic-related gene regulatory pathways. Results The incidence of breast tumors was 40% in DMBA-induced Tupaia belangeri. Compared with the control group, 30 metabolic differential products were detected in the serum of the group with breast cancer, with 18 down-regulated and 12 up-regulated (VIP> 1, P<0.05). KEGG pathway analysis revealed significant changes in four metabolic pathways: glutamate metabolism, glyceride metabolism, citric acid cycle, and alanine metabolism. Compared with the group without breast cancer, 18 metabolic differential products were detected, with 7 down-regulated and 11 upregulated (VIP>1, P<0.05). KEGG pathway analysis revealed significant changes in the citric acid cycle and glutamate metabolism. Compared with the control group, 31 metabolic differential products were detected in the serum of the groups without breast cancer, with 14 down-regulated and 17 up-regulated (VIP>1, P< 0.05). KEGG pathway analysis revealed significant changes in three metabolic pathways: glutamate metabolism, glyceride metabolism, and citric acid cycle. Conclusion Metabolomics analysis can reveal the characteristics of changes in metabolites in the serum of breast tumors. The results suggest that glutamate metabolism, glyceride metabolism, citric acid cycle, and alanine metabolism pathways are associated with the occurrence and development of DMBA-induced breast tumors in Tupaia belangeri. It provides a foundation for further research into the biological mechanism of breast cancer. [ABSTRACT FROM AUTHOR]

A fiber-hydrogel composite scaffold loaded with platelet-rich plasma was developed to simulate the microenvironment of breast tumor using mechanical and composition cues. The elemental composition and chemical structure were tested to confirm the successful loading of each component in the scaffold. The surface morphology and physicochemical properties of the scaffolds were characterized using scanning electron microscopy, swelling test, and water contact angle test. The study demonstrates that: the composite scaffold has appropriate pores for mass transfer as well as surface characteristics for cell adhesion. The fibers significantly improve the mechanical properties of the hydrogel, and the composite scaffold has similar mechanical properties to the breast tumor((4.79±0.45)kPa). Tumor cells cultured within this scaffold have higher proliferation capacities than 2D culture by a 33.1% improvement. The cells in the composite scaffold show the ability to assemble into spheres, and less sensitive to chemotherapy when compared with 2D culture and fiber-free. It is anticipated that this composite scaffold will be helpful for in vitro oncology studies and antitumor drug efficacy prediction. [ABSTRACT FROM AUTHOR]

The subject in this study was a female professional painter who underwent bilateral mastectomy because of bilateral breast cancer, experienced postoperative wound scarring, and developed alopecia due to the side effects of chemotherapy, which caused the patient to lose body image confidence and the motivation to engage in artistic creativity. The patient had shed tears early in the intervention and complained of difficulties with body image adjustment due to her altered appearance. Mastectomy patients must not only undergo drug treatment but also adjust psychologically to body image changes to decrease negative emotions. This was the author's motivation for involvement in this case. The nursing period was from 23 September to 30 December 2021. Physical, mental, spiritual, social, and family data were collected using observations and interviews. These data were evaluated and the main problems were determined to be disturbed body image related to altered body perception post- surgery, alopecia caused by chemotherapy, impaired physical mobility due to upper limb mobility limitations post-surgery, and nausea due to chemotherapy. The patient was encouraged to paint again and to use artistic creativity to comfort herself. Moreover, she was guided to express her innermost thoughts to face the impact of her changes in appearance. In addition, a care consultation channel was provided to facilitate experience sharing with other breast cancer patients, thus assisting the patient to cope with the mental impact of her treatments and face subsequent cancer treatments with a more positive attitude. Art therapy embraces a diverse variety of methods, including drawing and music. Art therapy is a valuable tool that facilitates both physical and mental healing. Based on this experience, nurses should include patients' close relatives when performing art therapy to facilitate shared care to overcome difficulties. We hope this nursing experience provides a practical reference for nurses. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the correlation between quantitative parameters of ultrasound elastic imaging and clinical stage and pathological molecular classification of benign and malignant breast tumors. Methods: 85 patients with breast mass admitted to our hospital from January 2020 to December 2022 were selected to undergo ultrasound elastic imaging examination. The pathological examination results of 85 patients with breast mass were analyzed, elastic imaging parameters of benign and malignant tumors were compared, and ROC curves were drawn for elastic strain rate, diameter change rate, area ratio and the three combined. The elastic imaging parameters of different clinical stages of breast cancer patients and the elastic imaging parameters of pathological molecular classification of breast cancer patients were analyzed. Results: Among 85 patients with breast mass, 35 cases were benign and 50 cases were malignant.The elastic strain rate, mass diameter, diameter change rate, mass area and area ratio in the malignant group were significantly lower than those in the benign group (P<0.05). The area ratio ROC curve AUC was 0.580, with 1.73 as the critical value, the diagnostic sensitivity and specificity of breast malignant tumor were 73.5% and 38.5%. The ROC curve of diameter change rate was 0.630 with 0.28 as the critical value. The diagnostic sensitivity was 75.5% and the specificity was 47.5%. The ROC curve of elastic strain rate was 0.790, with 15.2 cm2 as the critical value, the diagnostic sensitivity was 64.5%, and the specificity was 83.5%. The ROC curve was drawn with the three factors combined, and the AUC was 0.920, the diagnostic sensitivity was 82.5%, and the specificity was 92.5%. There were significant differences in the elastic strain rate, mass diameter, diameter change rate, mass area and area ratio in patients with breast malignant tumor at TNM stage Ⅰ, Ⅱ, Ⅲ and Ⅳ (P<0.05). Among them, the elastic strain rate, mass diameter, diameter change rate, mass area and area ratio of stage Ⅳ were significantly higher than those of stage Ⅲ, Ⅱ and Ⅰ, stage Ⅲ was significantly higher than those of stage Ⅱ and Ⅰ, and stage Ⅱ was significantly higher than those of stage Ⅰ. The differences of elastic strain rate, mass diameter, rate of diameter change, mass area and area ratio in Luminal A, Liminal B, Her2 overexpression and basal-like patients with breast malignant tumor were statistically significant (P<0.05). The elastic strain rate, mass diameter, rate of diameter change, mass area and area ratio of the Liminal B type are significantly higher than those of Luminal A, Her2 overexpression and basal-like type, and the overexpression of Her2 is significantly higher than those of Luminal A and basal-like type (all P<0.05). There was no statistical significance between Luminal A type and basal-like type (P>0.05). Conclusion: Ultrasound elastic imaging can be used for the diagnosis of benign and malignant breast tumors, and the quantitative parameters of ultrasound elastic imaging can be used to judge the clinical stage of malignant breast tumors, the Liminal type B, the Her2 overexpression type. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effect of breast piercing and surrounding needling combined with antibiotics in the treatment of lactation mastitis and its influence on the degree of pain and inflammatory factors of patients. Methods: 80 patients with mastitis during lactation in our hospital from January 2019 to December 2022 were selected as the research objects, and they were divided into observation group and Matched group with 40 patients in each group. The Matched group was treated with conventional antibiotics, and observed the clinical efficacy of the two groups of patients treated with breast piercing and peripheral needling combined with antibiotics.The changes of TCM syndrome scores before and 7 days Post-treatment, the visual analogue scale（VAS) scores at different times, the time of pain resolution, and the changes of inflammatory factor levels before and 7 days Post-treatment were compared. Results: The total response rate was higher in the observation group compared with the control group（P＜0.05); Pretherapy, there was no difference between the two groups in the scores of aversion to cold and fever, local skin burning, breast swelling and pain, and breast agglomeration symptoms（P＞0.05). Post-treatment, the scores of aversion to cold and fever, local skin burning, breast swelling and pain, and breast agglomeration symptoms in the two groups decreased, and the scores in the observation group were different with matched group（P＜0.05); There was no difference in VAS scores between the two groups pretherapy（P＞0.05). The VAS scores of patients in the two groups gradually decreased on the first day, the third day and the sixth day Post-treatment, and the observation group was lower than the matched group（P＜0.05). The time of pain relief in the observation group was different with matched group（P＜0.05); There was no difference in the expression of WBC, PCT and hsCRP between the two groups pretherapy（P＞0.05). Post-treatment, the expression of WBC, PCT and hsCRP in the two groups decreased, and the observation group was different with matched group（P＜0.05). Conclusion: Breast piercing and surrounding needling combined with antibiotics can improve the clinical efficacy of lactation mastitis, reduce the symptoms of aversion to cold and fever, local skin burning, breast swelling and pain, breast lump, etc., reduce the pain feeling and duration, and reduce the level of inflammatory factors in patients, which is worthy of clinical application and promotion. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

This article describes the nursing experience of treating a 98-year-old female breast cancer patient with bone metastasis in a hospice unit, including difficulties caused by Covid-19 pandemic prevention policies effecting the successful provision of end-of-life care. The nursing period was from May 14 to June 2, 2021. Data collection was performed through observation, interviews, physical examination, medical record review, and the four dimensions of assessment. The patient's primary health problems were impaired skin integrity, chronic pain, and spiritual distress. In addition to analgesic drugs, far-infrared, silver ion dressings and aromatherapy were used to relieve the patient's physical symptoms. However, the patient suffered from spiritual distress because her family could not visit her due to the epidemic preventive policies of Covid-19. By arranging video chat for the patient and her family, the author guided both of them to express the four themes of life (gratitude, apology, love, and goodbye) to each other in order to achieve the goal of hospice care. Hopefully, the nursing experience provides a reference for hospice caregivers in practicing end-of-life care during the Covid-19 pandemic. [ABSTRACT FROM AUTHOR]

In general, neuroendocrine cancer develops in the digestive or respiratory tract, and when it is found in other organs, it is often due to metastasis. Primary neuroendocrine carcinoma of the breast occurs very rarely, and the exact clinical picture, radiological findings, treatment and prognosis are not well known. Furthermore, only a small number of literature reports have been published. Here, we report the imaging findings of primary neuroendocrine carcinoma in the breast of a 51-year-old female, along with a literature review. [ABSTRACT FROM AUTHOR]

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

PD-1/PD-L1 inhibitors have emerged as an important therapeutic tool in breast cancer immunotherapy. However, certain scientific issues remain to be addressed urgently in immunotherapy for breast cancer, especially for triple-negative breast cancer (TNBC), including the poor efficiency of PD-1/PD-L1 inhibitor monotherapy, the lack of explicit biomarkers to effectively screen treatment-sensitive populations, and the high incidence of immune-related adverse events (irAEs). In order to improve the treatment efficacy and reduce the incidence of irAEs, it is important to take some measures, such as exploring combined treatment of PD-1/PD-L1 inhibitors and other drugs, using nanotechnology to develop nanocarriers that selectively target tumor cells to reduce the toxicity and increase the efficacy of antitumor drugs, exploring biomarkers that can predict the response potential of immunotherapy, and early identification and treatment of irAEs and the construction and development of a multidisciplinary team (MDT) model. As these measures are actively promoted and the problems continue to be solved, PD-1/PD-L1 inhibitors will certainly have a broader application prospect in the treatment of breast cancer. [ABSTRACT FROM AUTHOR]

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)